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Access and Use of Medications
in HIV Disease
Scott R. Smith and Duane M. Kirking
Objective. To examine if measures of access to medical care are associated with out-
patient use of antiretroviral and Pneumocystis carinii pneumonia (PCP) medications
among a cohort of individuals with HIV disease.
Data Sources. Adults who participated in a series of up to six interviews as part of
the AIDS Costs and Services Utilization Survey (ACSUS). ACSUS, a panel survey
of persons with HIV disease, was undertaken from 1991 through 1992.
Study Design. The Andersen Behavioral Model of Health Services Use provided the
conceptual framework for the study. Logistic regression analyses with generalized es-
timating equations were conducted to determine the effects of predisposing, enabling,
and need-for-care factors on the odds of antiretroviral or PCP medication use. The
analytic sample consisted of 1,586 respondents whose 7,652 interviews provided the
data.
Principal Findings. The multivariate analysis showed that being female (OR= 0.76;
95% C.I. = 0.60-0.95), ages 15 to 24 years (OR = 0.64; 95% C.I. = 0.44-0.92), and
having a hospitalization (OR= 0.73; 95% C.I. = 0.63-0.84) were associated with lower
odds of using antiretrovirals. African American race (OR = 1.30; 95% C.I. = 1.04-
1.62), having both public and private insurance (OR = 2.11; 95% C.I. = 1.47-3.03),
attending counseling (OR = 1.17; 95% C.I. = 1.02-1.34), having a usual source of
care (OR = 1.70; 95% C.I. = 1.38-2.11), and clinical trials participation (OR = 1.52;
95% C.I. = 1.23-1.87) were associated with a higher odds of use. Similar results were
obtained for analyses of PCP medication use.
Condusions. Sociodemographic differences exist in access and use of prescription
drugs within the ACSUS cohort. The results suggest that women and those ages 15 to
24 years have poor access to some medications that improve survival in HIV disease.
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Early detection of human immunodeficiency virus (HIV) infection and im-
proved drug therapies have prolonged survival in a growing number of
individuals. Over the past 15 years, the clinical course of HIV disease has
shifted from short and rapidly lethal to chronic and episodic. Likewise,
medical care for HIV-related conditions has broadened beyond merely sup-
portive and palliative care to include the prevention of perinatal transmission
(Centers for Disease Control and Prevention [CDC] 1994), prophylaxis of
AIDS-opportunistic illnesses (CDC 1997a), and treatment with antiretroviral
therapy (CDC 1998). As a result, substantial declines in the incidence of
perinatally acquired HIV (CDC 1997b), AIDS-opportunistic illnesses, and
AIDS-related deaths (CDC 1997c) have been associated with the increasing
use of prenatal antiretroviral drugs and the market availability of highly
active antiretroviral agents (Palella, Delaney, Moorman, et al. 1998). This
trend suggests that the continued decline of AIDS incidence will largely
be influenced by levels of access and adherence to medication regimens by
individuals with HIV disease.
The first studies ofthe medication utilization patterns ofHIV-infected in-
dividuals were predominantly conducted in cohorts ofmen who have sex with
men (Graham, Zeger, Kuo, et al. 1991; Lang, Osmond, Samuel, et al. 1991;
Holmberg, Conley, Buchbinder, et al. 1993). Among this group, investigators
typically found that white males with higher educational attainment, health
insurance, and HIV symptoms were the more frequent users of HIV-related
drug therapies. One longitudinal study that examined access to therapy by
homosexual and bisexual men found that previous HIV-related hospitaliza-
tion, having a prior outpatient visit, insurance status, college education, and
being white were all associated with antiretroviral use for persons without
clinical AIDS (Graham,Jacobson, Kuo, et al. 1994).
Consistent with earlier research, other studies in more diverse samples
of HIV-infected patients have indicated that racial differences exist in the
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use of HIV-related medications. For example, Moore and colleagues (1994)
found that African Americans were significantly less likely than whites to
receive antiretroviral therapy or PCP prophylaxis. Correspondingly, the
1995 to 1996 national decline in AIDS-opportunistic illnesses and deaths
have been proportionally less for African Americans and Hispanics than for
whites (CDC 1997c). Taken together, these racial differences suggest that
socioeconomic and cultural factors, which are often correlated with race
(Schulman et al. 1995; Schechter, Hogg, Aylward, et al. 1994; Simon et al.
1995), may be especially influential in determining access and utilization of
HIV-related drug therapy.
Another group that reportedly has had lower rates of medication use
is women with HIV disease (Moore et al. 1991; Stein, Piette, Mor, et al.
1991; Hellinger 1993). Lower utilization is consistent with reports showing
that survival for women is generally shorter than it is for men following an
AIDS diagnosis (Blum, Sing, Gibbons, et al. 1994) and trends indicating
that the incidence of AIDS-opportunistic illnesses in women continues to
increase while in men it is declining (CDC 1997d). Turner, Markson, McKee,
et al. (1994) studied Medicaid beneficiaries with AIDS and found that for
those who were not injection drug users, men were twice as likely as women
to receive zidovudine. However, the investigators were unable to evaluate
whether men and women were at different stages of the disease. Disease
severity is a particularly important confounder in a Medicaid population
because women often qualify for benefits as a result of having dependent
children. Hence, women can become eligible for Medicaid benefits at an
earlier stage of disease whereas men are likely to become eligible at a more
advanced stage. Since other patient populations of women typically gain
access to the healthcare system more frequently than men do, reports oflower
use of antiretrovirals seemingly reflect unique barriers to using medications by
HIV-infected women. Although previous studies indicate that women with
HIV disease have a pattern of antiretroviral use that differs from that of
men, whether lower access is associated with differences specifically related
to gender, socioeconomic factors, or disease stage has not been addressed.
This study examines a model of outpatient medication use by individu-
als with HIV disease. The conceptual framework for the study is the Andersen
Behavioral Model of Health Services Use (Andersen and Newman 1973). We
hypothesized that (a) predisposing, enabling, and need-for-care measures of
access are associated with the use of outpatient prescription medications;
(b) the association between measures of access and medication use differ
according to disease stage; and (c) after controlling for medical need and
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enabling factors, racial-ethnic minorities, injection drug users, and women
would have lower access to HIV-related medications.
METHODS
Data Source
This study used data from the AIDS Costs and Services Utilization Survey
(ACSUS). ACSUS is an observational panel survey of the costs and use of
medical services by persons with HIV disease (Berk, Maffeo, and Schur 1993).
An important strength of the ACSUS data is the survey's broad diversity of
participants from different geographic areas, racial and ethnic backgrounds,
routes of HIV exposure, and insurance status. In addition, the ACSUS data
include predisposing, enabling, and need-for-care measures as hypothesized
in the Behavioral Model. Similarly, the ACSUS data have been used by
Fleishman, Hsia, and Hellinger (1994) to study medical service utilization
with the Behavioral Model providing a conceptual framework.
In the ACSUS, a series of six personal interviews were conducted over
an 18-month period, from 1991 to 1992. In addition to taking part in the
interviews, participants signed consent forms that granted permission for the
investigators to contact medical and nonmedical providers of services. The
researchers examined medical records using a checklist of 75 conditions com-
monly found in HIV-infected patients. In addition, data collection included
longitudinal information about the use of prescription drugs. In the current
study, these data are linked to longitudinal information about the predis-
posing, enabling, and need-for-care characteristics of the participants. This
link offers an analytical advantage over past drug utilization studies to assess
important confounders and effect modifiers in examining drug utilization.
Disease Staging
In the current study, the date ofAIDS diagnosis and occurrence of conditions
as obtained from the ACSUS checklist were used to derive a disease stage of
participants at each interview wave. Individuals were classified at each wave
as asymptomatic, HIV-symptomatic, or having AIDS. This classification
method was analogous to the approach used when the original ACSUS
sample was drawn (Berk, Maffeo, and Schur 1993) and to the approach used
by Fleishman, Hsia, and Hellinger (1994).
AIDS was defined using a slightly modified version of the 1987 CDC
surveillance case definition (CDC 1987). Participants were considered to have
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AIDS beginning with the date on which either an indicator disease or AIDS
was diagnosed and appeared in their medical record. Participants who did not
meet the 1987 case definition for AIDS, but who had conditions that could
be attributable to HIV infection, were categorized as HIV-symptomatic.
This classification scheme was based on a review of the literature and on
information from the 1993 CDC revised classification for HIV infection
(CDC 1992). All other participants whose medical records were reviewed
but who did not meet the selection criteria for AIDS or HIV-symptomatic
status were classified as asymptomatic.
Statistical Methods
To examine factors associated with prescription drug utilization over time,
logistic regression analyses were conducted. The primary response variable
was self-reported prescription medication use during each interview reference
period. Utilization was coded as a binary variable depending on whether or
not a respondent reported taking specific drugs during a reference period.
Separate regression analyses were performed using two discrete categories
of drugs-antiretrovirals and PCP medications-as the response variable.
These categories ofdrugs were chosen because barriers (Hendrickson, Nevins,
Chesnut, et al. 1993) and inequities (Stein, Piette, Mor, et al. 1991; Moore
et al. 1994; Graham, Zeger, Kuo, et al. 1991) have been reported regarding
access to these drugs. Moreover, these medications were the mainstays of
drug therapy when the ACSUS data were collected, and they continue
to be important components of the medication regimens used in treating
HIV disease. Antiretroviral utilization was defined as self-reported use of
zidovudine, didanosine, or zalcitabine. Similarly, PCP medication use was
derived from a participant's report of using sulfamethoxazole-trimethoprim,
pentamidine, dapsone, or pyrimethamine.
Because six consecutive interviews were conducted and, therefore, six
responses were possible from one individual, responses from the same in-
dividual were correlated. Analyses using conventional regression methods
could have provided erroneous variance estimates and loss of statistical
efficiency because of the conventional assumption that each response is sta-
tistically independent (hang and Zeger 1993). As a result, invalid conclusions
could have been made ifthe conventional approach had been applied to these
longitudinal data. Therefore, parameters of the regression models for both
the bivariate and multivariate analyses were estimated using the generalized
estimating equation (GEE) methods of Zeger and Liang (1986). The GEE
approach specifies the likelihood of the marginal probability distribution of
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a subject's response and a "working" covariance matrix for the observation
vectors (Ware, Lipsitz, and Speizer 1988). Consequently, this approach mod-
els the regression of the response variable on the independent variables and
also accounts for the correlated nature ofthe responses. The GEE method has
been shown to give consistent and valid estimates ofthe regression parameters
and of their variances for serial data (Liang and Zeger 1993).
Comparison ofRespondents Included and Excluded
from the Analyses
Only interviews with complete information for all variables of interest at a
given interview wave were included in the analyses. In addition, 53 interviews
(0.7 percent) were excluded from the analyses because the respondent was
hospitalized for the entire period of observation. To compare respondent
characteristics of those interviews that were excluded because of missing data
with those that were included, logistic regression models were constructed
using the GEE approach. The response was a binary variable indicating
whether an interview was included in the analytic sample or excluded. Inter-
views by individuals who were nonwhite were more likely to be excluded (25
percent nonwhite versus 21 percent white, p < .05). A further examination
of race/ethnicity showed that interviews by African Americans1 were more
likely to be excluded than those of whites (28 percent African American
versus 21 percent white, p< .05). However, no statistical difference was found
between whites and Hispanics or "other" races in terms of being excluded
from the analyses. In addition, interviews by respondents who had AIDS at
the time of the ACSUS screener questionnaire were also significantly more
likely to be excluded as a result of missing data (32 percent AIDS versus 20
percent non-AIDS, p < .05). There were no statistical differences in interview
status based on gender, injection drug using status, or level of education.
The most common reason for excluding an interview was missing
information about CD4+ cell count. Of the 10,045 completed interviews,
nearly 15 percent were excluded because there was no corresponding T-cell
measurement. The second most common item of missing information was
whether the respondent had a usual source of healthcare (4 percent). For
each of the other variables examined, less than 2 percent of the information
was missing. The final analytic sample consisted of 1,586 individuals who
provided 7,652 interviews of panel data. Of the respondents included in the
analyses, 67 percent provided five or six interviews, 19 percent provided three
or four interviews, and 14 percent provided one or two interviews.
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RESULTS
Sample Characteristics
Characteristics of the analytic sample are shown in Table 1. The sample was
predominantly male (82 percent) but demographically diverse in race/ethni-
city (42 percent white, 29 percent African American, and 27 percent His-
panic). Medical records indicated that injection drug use was a suspected
mode ofHIV exposure in approximately one-third of the respondents. Most
of the sample reported public (52 percent), private (27 percent), or public
and private (6 percent) insurance coverage. In addition, the distribution of
individuals categorized at each disease stage was approximately equal (30
percent asymptomatic, 35 percent HIV-symptomatic, and 35 percent with
AIDS). Notably, the sample characteristics were very similar to those reported
in the study of the ACSUS cohort by Fleishman, Hsia, and Hellinger (1994).
Unadjusted Odds Ratios of Characteristics Associated with
Medication Use
Unadjusted odds ratios, 95 percent confidence intervals, and significance tests
are presented in Table 1 for the association between individual characteristics
and outpatient medication use for all six interview waves. For predisposing
characteristics, the odds for women using either antiretroviral or PCP medi-
cations were significantly lower than they were for men. Similarly, the odds
that persons ages 15 through 24 years were using either drug category was
significantly lower than for the 25 through 34-year-old age group. For each
category of drug, having a college education was associated with increased
odds of medication use. Individuals who were African American or Hispanic
were significantly less likely to use PCP medications.
Of the enabling characteristics, health insurance was the variable most
strongly associated with medication use. There was a twofold increase in the
odds of using antiretrovirals and PCP medications for individuals who had
both private and public insurance as compared to the uninsured. Having
private health insurance increased the odds of use by more than 50 percent.
Likewise, individuals with public health insurance were 47 percent more
likely to use antiretrovirals and 57 percent more likely to use PCP medica-
tions. Finally, clinical trial participation (data not shown) and having a usual
source of healthcare were significantly associated with the use of both drug
categories.
Consistent with previous investigations that have applied the Behavioral
Model ofHealth Services Use (Aday, Lee, Spears, et al. 1993; Nichol, Stimmel,
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Table 1: Characteristics of the Analytic Sample, Unadjusted Odds
Ratios, 95% Confidence Intervals, and Significance Tests for the
Association Between Individual Characteristics and Outpatient
Prescription Drug Use in the ACSUS, N=1,586
Antiretrovirals PCPMedications
No. % OR 95% C.L % OR 95% CI.
Intriews User User

















25 to 34 years: 660 (41.6%) 3243
15 to 24 years: 88 (5.5%) 456
35 to 44 years: 620 (39.1%) 2912
45 to 54 years: 167 (10.5%) 818
55 and over: 51 (3.2%) 223
Education
< High school: 849 (53.5%) 4028
College+: 737 (46.5%) 3624
IV Drug Use
None: 1088 (68.6%) 5291
Yes: 498 (31.40/) 2361
Insurance
Uninsured: 222 (14.3%) 774
Public only: 813 (52.3%) 4370
Private only: 424 (27.3%) 2080
Both types: 96 (6.2%) 428
Income
0 to $350 a month: 447 (28.3%) 1380
$351 to 1300 a month: 735 (46.5%) 4132
$1301 to 4001 a month: 398 (25.2%) 2140
Usual Source
None: 93 (5.9%) 450
Yes: 1484 (94.1%) 7202
Stage ofDisease
Asymptomatic: 462 (30.0%) 1732
HIV-symptomatic: 533 (34.7%) 2861
AIDS: 543 (35.30/) 3059
CD4+ Cell Count
> 500 cells/ll: 170 (12.7%) 882
301 to 500 cells/,ul: 292 (21.80/) 1572
50 to 300 cells/Al: 558 (41.60/) 3283
0 to 49 cells/,ul: 321 (23.9%) 1915








0.91 0.74-1.11 44 0.73**
1.00 0.81-1.24 43 0.69***









































































tFor characteristics that could change over time, the frequency reported is for the characteristic at time 1. Data on disease stage,
insurance status, usual source of care, and monthly income were missing at time 1 for some participants.
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and Lange 1995), need-for-care variables were among the strongest associated
with drug utilization. As shown in Table 1, CD4+ cell count was strongly
associated with the two categories of HIV-related drugs. Individuals with a
low CD4+ cell count were significantly more likely to be taking antiretrovirals
or PCP medications than were persons with a high CD4+ cell count. In almost
every instance, this significance was at p < .0001 and the magnitude of the
odds ratios was relatively large.
Multivariate Analysis ofAccess and Use ofAntiretrovirals
Results from the multiple logistic regression analysis of outpatient antiretrovi-
ral use are presented in Table 2. After adjusting for medical need and enabling
resources, women were significantly less likely to be taking antiretroviral
drugs. Women, as compared to men, had only about three-quarters of the
odds of using antiretrovirals. Similarly, adolescents and young adults ages 15
through 24 were also less likely than those ages 25 to 34 years to receive an-
tiretroviral agents. After adjusting for other covariates, African Americans and
Hispanics were more likely to be using antiretroviral agents than were whites.
Several enabling variables were also associated with antiretroviral use.
Individuals who had public and private insurance were still twice as likely to
be antiretroviral users even after adjusting for other variables in the model.
Likewise, having an income of $1,301 or more a month increased the odds
of using antiretrovirals. Those who attended a support group or received
psychological counseling, clinical trial participants, and those with a usual
source of healthcare were all more likely to be antiretroviral users.
In comparing the adjusted odds ratios of predisposing, enabling, and
need-for-care variables found in Table 2 with the unadjusted odds ratios found
in Table 1, there appears to be very little confounding, with the notable
exception of race. Further, interactions between gender and injection drug
use, racial-ethnic group, and insurance status were tested and found not to be
statistically significant.
Analysis by Disease Stage
Other studies that have examined the use of antiretrovirals have found multi-
ple interactions between several independent variables and the stage ofHIV
disease (e.g., Graham,Jacobson, Kuo, et al. 1994). This analysis ofthe ACSUS
data also found similar interactions with variables such as gender, education,
and race. To investigate these interactions further, separate analyses were
conducted for the three stages of disease. Table 3 presents the results from
three separate logistic regression models according to disease stage. At each
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Table 2: Results From A Multiple Logistic Regression Analysis of
Outpatient Antiretroviral Use in the ACSUS, 1991-1992 (N = 1,586)
Variabk OR 95% CL. p-Robust
Gender Male 1.00
Female 0.76 0.60-0.95 .0161
Age 25 to 34 years 1.00
15 to 24 years 0.64 0.44-0.92 .0155
35 to 44 years 1.05 0.87-1.28 .6010
44 to 54 years 1.54 1.12-2.13 .0079
55 years and older 1.70 1.05-2.75 .0319
Race/Ethnic Group White, non-Hispanic 1.00
African American, non-Hispanic 1.30 1.04-1.62 .0187
Hispanic 1.38 1.11-1.72 .0044
Other 1.30 0.60-2.81 .4982
Injection Drug Use None 1.00
Yes 1.05 0.86-1.28 .6269
Insurance Uninsured 1.00
Private only 1.42 1.08-1.88 .0134
Public only 1.53 1.24-1.90 .0001
Private and public 2.11 1.47-3.03 .0001
Income $0 to $350 a month 1.00
$351 to $1300 a month 1.20 1.05-1.38 .0061
$1301 or more a month 1.43 1.16-1.75 .0007
Receiving Home Help No 1.00
Yes 0.81 0.71-0.93 .0024
Counseling or Group No 1.00
Support Yes 1.17 1.02-1.34 .0211
Hospitalization No 1.00
Yes 0.73 0.63-0.84 <0001
Ambulatory Visits None 1.00
1 to 2 visits 1.83 1.56-2.14 <0001
3 or more visits 2.09 1.78-2.45 <.0001
Usual Source of Care No 1.00
Yes 1.70 1.38-2.11 <.0001
Participate in Clinical No 1.00
Trials Yes 1.52 1.23-1.87 .0001
Perceived Health Status Excellent or very good 1.00
Good 0.91 0.79-1.05 .2009
Fair 0.78 0.65-0.93 .0050
Poor 0.64 0.51-0.80 .0001
CD4+ Cell Count > 500 cells/gl 1.00
301 to 500 cells/pl 4.52 3.40-6.01 <.0001
50 to 300 cells/pl 7.10 5.36-9.40 <0001
0 to 49 cells/Al 4.32 3.18-5.89 <0001
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ofthe three stages, a significant association is found between CD4+ cell count,
having a usual source ofhealthcare, and ambulatory healthcare visits, and the
use of antiretrovirals. These results are consistent with those found in Table
2, which included the entire ACSUS sample. However, the association of
other independent variables from the Behavioral Model varies in significance
depending on the disease stage.
At the asymptomatic stage of HIV disease, none of the predisposing
conditions were associated with use of antiretrovirals. Instead, use was associ-
ated with enabling and need-for-care factors. In addition to the factors named
earlier, high income and clinical trial participation were also associated with
antiretroviral use among those who were asymptomatic.
At the HIV-symptomatic stage, several factors were significantly as-
sociated with antiretroviral use that were not found to be associated with
use in the other two disease stages. These factors were the predisposing or
enabling characteristics of gender, young age, income, insurance status, and
counseling/group support attendance.
For individuals with AIDS, the only predisposing characteristic asso-
ciated with medication use was race. Individuals who were not white were
60 percent more likely than whites to use antiretrovirals. Moreover, race
was significantly associated with antiretroviral use only among those with
AIDS and not among participants at the other two disease stages. Receiving
help at home, past hospitalization, and an excellent health perception were
all factors that reduced the odds of medication use and were found to be
uniquely associated only at the AIDS stage. As with individuals who were
asymptomatic, clinical trial participation was associated with antiretroviral
use for people with AIDS.
Multivariate Analysis ofAccess and Use ofPCPMedications
Table 4 shows the results, from multiple logistic regression analyses, of factors
associated with medications used to treat and prevent PCP. The middle
columns show factors associated with use in the entire sample, and the last
columns show factors associated with use in the subset of individuals who
had CD4+ cell counts of less than 200 cells/,uil or had a history of PCP. Both
models produced similar results.
In comparing PCP medications with antiretrovirals, there are several
factors associated with use of both medication categories. In both models,
gender, young age, insurance status, income, receiving help at home, counsel-
ing/group support, ambulatory visits, usual source of care, perceived health,
and CD4+ cell count were associated with use. The main differences between
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Table 4: Results from a Multiple Logistic Regression Analysis of






Age 25 to 34 years 1.00
15 to 24 years 0.54** 0.37-0.78
35 to 44 years 0.99 0.82-1.18
44 to 54 years 0.86 0.66-1.12
55 years and older 0.81 0.52-1.27
Race/Ethnic White, non-Hispanic 1.00




Drug Use Yes 0.89 0.74-1.07
Insurance Uninsured 1.00
Private only 1.44** 1.09-1.90
Public only 1.61**** 1.30-2.00
Private and public 1.94*** 1.40-2.70
Income $0 to $350 a month 1.00
$351 to $1300 a month 1.14 1.00-1.31
$1301 or more a month 1.44*** 1.19-1.76
Receiving No 1.00
Home Help Yes 1.25*** 1.10-1.41
Counseling or No 1.00




Visits 1 to 2 visits 1.55**** 1.31-1.84
3 or more visits 2.01**** 1.70-2.39
Usual Source No 1.00
ofCare Yes 1.46*** 1.17-1.82
Participate in No 1.00
Clinical Trials Yes 1.07 0.92-1.26
Perceived Excellent or very good 1.00
Health Good 1.32**** 1.15-1.51
Status Fair 1.46**** 1.25-1.71
Poor 1.16 0.94-1.41
CD4+ Cel >500 cels/gl 1.00
Count 301 to 500 cells/gl 1.59* 1.11-2.27
50 to 300 cells/,ul 8.08**** 5.66-11.52
0 to 49 cells/pl 11.05**** 7.53-16.22
*p< .05; **p< .01; *** p< .001; **** p< .0001.
Only Participants with CD4+ CeU
Counts <200 celUs/lI or a History







































Access and Use ofHIVMedications
the two utilization models were in the predisposing and enabling factors
associated with use.
For antiretrovirals, the predisposing conditions include older age groups
and race, whereas for PCP medications these factors were not significantly
associated with use. Likewise, previous hospitalization and participation in
clinical trials were enabling variables associated with the use of antiretroviral
drugs but not with PCP medications. Another difference was in the direction
of the association of the perceived health variable. Although perceived health
was associated with medication use in both models, those who perceived
their health to be less than "very good" were more likely to take PCP
medications and less likely to take antiretrovirals. Similarly, receiving help at
home decreased the odds of using antiretrovirals but increased the odds of
using PCP medications.
DISCUSSION
An important finding of this study is that the odds that women use antiretro-
virals and PCP medications are significantly less than the odds that men use
them, even after adjusting for socioeconomic and health status differences.
This finding is consistent with the low use of antiretrovirals and prophylactic
medications by women in the HIV Epidemiology Research Study (HERS)
(Solomon, Stein, Flynn, et al. 1998) and corroborates the results of others
(Stein, Piette, Mor, et al. 1991; Turner, Markson, McKee, et al. 1994). If it
is borne out by further studies in today's era of highly active antiretroviral
therapy, this finding has important implications for health policy and plan-
ning. In particular, the identification of ways to improve access and the use
of medications by women with HIV disease is needed.
It is interesting that the female participants had a lower use of antiretro-
virals and PCP medications, because in non-HIV patient groups women
generally have a higher use of prescription drugs. This finding is not easily
explained. It is possible that the women in theACSUS were healthier than the
men were. However, since the analyses controlled for CD4+ cell count, this
does not seem likely. Others have also suggested that differences in gender
roles, social conditions, and AIDS-related medical care may affect the access
of HIV-infected women to treatment (Ickovics and Rodin 1992). Because
women in the ACSUS sample were more likely to be African American and
poorer than the men were (Hellinger 1993), unmeasured factors associated
with poverty and culture may be affecting a woman's use of HIV-related
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medications. Alternatively, it should be acknowledged that providers in this
time period might have had concerns about the potential effects on the fetus
of antiretroviral drugs if a woman were to become pregnant. Thus, providers
might less likely have prescribed these medications to women because of
these medical concerns.
A limitation of the current study was that the ACSUS data did not
contain belief and attitudinal variables. One investigation has shown that
some women with HIV experience unique psychological or social barriers to
using antiretroviral medications (Siegel and Gorey 1997). Because AIDS was
first diagnosed in gay and bisexual men, early studies were predominantly
conducted in this group, so less is known about the natural history and
psychosocial mechanisms influencing the course ofHIV infection in women
(Ickovics and Rodin 1992). Further, social service organizations began their
outreach efforts in communities of gay and bisexual men. As a result, women
may be less connected with community or patient information groups that
provide educational materials on these medications (Jeffe et al. 1998). Hence,
more research is needed on the psychosocial characteristics ofmedication use
by women with HIV disease. Although health beliefs were not included in the
ACSUS study, this does not limit the central finding that gender differences
exist in the use of HIV-related medications.2
Another important result was the finding of a significantly lower use
of medications by young persons ages 15 through 24 years in the ACSUS.
Other studies that have examined access to drug therapy in HIV disease
either have not considered age (Stein, Piette, Mor, et al. 1991) or have
modeled age as a dichotomous variable (Graham, Jacobson, Kuo, et al.
1994; Moore et al. 1994). Because the use of most medications changes
with age, the finer gradations of age used in the current study provide a
more meaningful examination of its effect on the odds of use. The lower
use of prescription medications by younger respondents with HIV may be
related to the behavioral, psychological, and social factors that put adolescents
and young adults at increased risk for HIV infection. These include the
tendency to engage in high-risk behavior, a sense of invulnerability, less
well developed coping styles, and less access to age-appropriate social and
medical services (Hein 1989; Ickovics and Rodin 1992). Vermund, Hein,
Gayle, et al. (1989) have proposed that adolescents most likely to be infected
with HIV include "disenfranchised" youths such as runaways, injection drug
users, and sex workers. Inexperience with the healthcare system and with
taking prescription medications (especially those with frequent side effects)
may further contribute to a lower use of antiretrovirals by young people. The
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results of this study point to a need to develop age-appropriate medical and
pharmaceutical care services for youths with HIV disease.
The association of access to the use of antiretroviral drugs appears to
differ by stage of the disease. The findings indicate that, at the early stages,
access to antiretrovirals is equitable with the possible exception of access
for those with very high incomes relative to those with very low incomes.
However, several unique differences in predisposing and enabling measures
appeared at the HIV-symptomatic stage. Hence, problems with access seem
to occur after individuals show symptoms ofthe HIV infection but before they
are diagnosed with AIDS. Since government assistance programs sometimes
impose medical eligibility requirements related to CD4+ cell counts or AIDS
diagnoses (Buchanan and Smith 1996), symptomatic individuals may have
trouble obtaining assistance and consequent access to medications. This find-
ing is especially provocative in the current era of highly active antiretroviral
therapy, because early treatment is now recommended for most people with
detectable plasma HIV RNA (CDC 1998).
The separate analysis where respondents had AIDS revealed that non-
white individuals were significantly more likely to use antiretrovirals. This
finding was unanticipated and was contrary to our hypothesis, which was
based on previous studies (e.g., Stein, Piette, Mor, et al. 1991; Moore et al.
1994; Crystal, Sambamoorthi, and Merzel 1995). However, racial differences
may depend on the stage of disease, which is often related to the time at
which an individual initially presents for medical care. Therefore, these results
should be interpreted with caution in that the sample consists of patients who
were receiving medical care during the recruitment phase of the ACSUS
study. As a result, participants had some level of access to the healthcare
system. In addition, African Americans were more likely to be excluded from
the analysis because of missing data. Thus, the African American participants
included in the analyses might have been atypical in their outpatient use of
antiretrovirals.
Notably, there was a significant increase in medication use among those
who attended a support group or who received psychological counseling.
Not only was this result consistent for both drug categories in analyses that
predicted medication use, but also in other analyses that examined the in-
tensity of use (results not shown). In contrast, the use of alternative therapies
(defined broadly as therapies such as holistic medicine or biofeedback) was
not related to medication use in any of the multivariate analyses. Possibly, in-
dividuals who attend support groups or receive psychological counseling are
more inclined to use medications or to report medication use. Alternatively,
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social-psychological factors such as social support and reinforcement, obser-
vation of role models, normative pressure to use medications, and diffusion
of information may be influencing support group attendees and individuals
in counseling to ultimately use prescription medications. More research is
needed to understand this association.
This study is one of only a few that include clinical trial participation
and usual source of healthcare as measures of access to drug therapy in HIV
disease. The significant association of these two enabling measures with the
use of antiretroviral drugs underscores the importance of these measures in
predicting antiretroviral use. Because clinical trials tend to enroll persons
with particular sociodemographic characteristics (Diaz, Chu, Sorvillo, et al.
1995; Cunningham, Bozzette, Hays, et al. 1995), it is important to adjust
for the effects of participation when one assesses the association of access
measures with medication utilization. The results from the current study
suggest that clinical trial participation is an important factor related to access
to antiretrovirals and that the maglnitude of the association is about the same
as having health insurance coverage.
A central limitation of the study was that information about prescrip-
tion drug benefits (as compared to overall health insurance coverage) was
unavailable. Although all Medicaid programs provide prescription drug ben-
efits (Buchanan and Smith 1994), utilization limits, copayments, and prior
authorization policies often weaken Medicaid prescription drug benefits.
Furthermore, Medicaid payment levels for drugs related to HIV infection are
more often below the payment levels of private health insurance companies.
Likewise, private health insurance plans do not always provide prescription
drugs as a covered benefit. Since Medicaid programs vary in medication
coverage, a direction for future research is to examine State variations in HIV
medication utilization rates. To the extent that prescription drugs are not cov-
ered by the health insurance plans of the respondents, the results of this study
underestimate the effects of health insurance coverage on medication use.
Finally, this study is limited by the ACSUS sampling frame, which
consisted of patients receiving medical care during the recruitment phase of
the study. Rural areas and regions of the country with low incidence of HIV
were excluded from the ACSUS sample (Berk, Maffeo, and Schur 1993).
For these reasons, participants are not representative of the U.S. population
with HIV infection (Berk, Maffeo, and Schur 1993). However, researchers
are collecting information on a nationally representative sample of people
receiving care for HIV infection as part of the HIV Cost and Services
Utilization Study (HCSUS). Information from the HCSUS study holds the
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potential for a further assessment of the differences in access and medications
use found in this disease.
Although new antiretroviral medications have been developed since
the time of the ACSUS, the medications examined in this study continue to
be important components of the combination regimens recommended for
HIV infection (CDC 1998) and for the prevention of PCP (CDC 1997a).
As more potent and effective medication regimens become available, the
importance of access to drug therapy will become increasingly crucial in
enabling people with HIV disease to live longer and to suffer fewer compli-
cations. The results from this study indicate that factors other than medical
need are important determinants of medication use in contending with this
life-threatening disease.
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NOTES
1. Editor's note: References to the black race have been changed to "African Ameri-
can" in keeping with the policy of Health Services Research.
2. Hellinger (1993) found that asymptomatic women were less likely to receive
zidovudine but that there were no gender differences among individuals who
were symptomatic or who had AIDS. In the current study, the separate analysis
of interviews by asymptomatic respondents indicated that women were no more
or less likely to receive antiretrovirals than were men. Similarly, responses by those
with AIDS at the time of the interview showed no likelihood differences between
men and women. However, a difference in medication use was found at the HIV-
symptomatic stage of disease. HIV-symptomatic women in the current study were
significantly less likely to use antiretrovirals than were HIV-symptomatic men.
These results differ from those of Hellinger for two main reasons. First Hellinger
controlled only for type of health insurance, income, and intravenous drug use in
his analysis. Hence, the multivariate regression equations explaining zidovudine
use were different from those modeled in the current study. Second, the response
variable in Hellinger's work was zidovudine use. The current study considered
three antiretrovirals that reportedly were used. As a result, differences may exist as
a consequence of including the use of the three antiretrovirals that were available
at the time of the study instead of including just zidovudine.
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